DFTX vs VNDA
DFTX: Definium is applying scientific rigor to psychedelics and empathogens to develop FDA-breakthrough-designated treatments for anxiety, depression, PTSD, and autism. VNDA: Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in dermatology, rare diseases, and oncology.
Side-by-side fundamentals
| Metric | DFTX | VNDA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $43.67 | $5.35 | |
| Market cap as of 2026-07-23 | $5.8B | $329M | |
| PEG as of 2026-07-23 | -0.13 | -0.00 | DFTX lower |
| Net margin as of 2026-07-23 | n/a | -110.0% | |
| Gross margin as of 2026-07-23 | n/a | +94.2% | |
| Operating margin as of 2026-07-23 | n/a | -73.6% | |
| ROE as of 2026-07-23 | -102.5% | -61.4% | VNDA higher |
| ROA as of 2026-07-23 | -70.7% | -44.6% | VNDA higher |
| Debt / equity as of 2026-07-23 | 0.15 | 0.03 | VNDA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +8.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -5.3% | |
| Beta as of 2026-07-23 | 2.29 | 0.62 | |
| 1-year return as of 2026-07-22 close | +353.1% | +13.6% | DFTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.